Inflammatory bowel diseases
-
Inflamm. Bowel Dis. · Jul 2010
Randomized Controlled Trial Multicenter StudyRandomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD). We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD. ⋯ Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.